About: Mr. Ramanbhai B. Patel (Late)
About: Mr. Ramanbhai B. Patel (Late)
About: Mr. Ramanbhai B. Patel (Late)
IN THE COMMUNITY
Shodh: Research
Promoting research in pharmaceuticals and healthcare through the biennial
symposium, The Ramanbhai Foundation International which brings together the
scientific community from across the world, both from academia and industry
who deliberate upon unmet medical needs, new research initiatives and some
latest advancements in healthcare and medical science.
HUMAN RESOURCES
Building people capabilities and providing them platforms and opportunities to
grow and spread their wings has always been a unique strength of the organisation.
An essential part of Zydus value proposition is ‘GROW’, which looks at Global
opportunities; Respect, recognition, care and building talent from within;
Opportunities across the value chain and Working with the best. Zydus build People
to Build the Business – was the motto since 1995, and the HR team has been
focusing its efforts on this ethos at every step of the journey as they grew into a
multi-locational, innovation-driven global healthcare company.
During the year, the HR initiatives have focussed on –
Talent management:
In keeping with the changing business and technological landscape, a
technical competency framework has been built for the teams driving innovation,
operations and the commercial cluster. This framework is being used for hiring talent
and developing internal talent. A customised framework for the marketing team has
also been created, as a part of which all product managers and brand manager will
undergo a brand building competency programme.
Talent pool:
A group of young and prospective leaders were taken through a structured
leadership development programme called LEAP in which business objectives were
linked to their individual roles and career development and business projects were
linked to their individual development based on leadership competencies.
Manufacturing excellence:
For the manufacturing teams, the Company has mapped critical processes,
machines and the expected levels to drive productivity and performance. Hiring
guidelines have been created for all the critical products based on critical machine
and processes. Skills matrix has been mapped for all manufacturing employees and
the development journey for skills development is underway. As a part of the
capability building initiatives, FTEs are being enrolled for customised education
programmes.
INDIA BUSINESS
The India Business comprises the India formulations business spearheaded
by Zydus Healthcare Ltd., based in Mumbai and the Biologics business which drives
the sales and marketing of biosimilars and novel biologics. Zydus Healthcare Ltd.
Zydus is one of the oldest players in the Indian formulations market and has gone
onto become a prominent pharmaceutical manufacturer in India. Besides
continuously improving its market presence and market share, the group has also
expanded its portfolio by entering newer therapeutic areas.The group has been
launching new products with the first mover advantage and has a strong presence in
both acute and chronic therapies.
These strategic initiatives have helped Zydus become one of the dominant
players in the Indian formulations market with the leadership position in several
therapeutic categories. The group’s innovative NCE therapy Lipaglyn, a novel drug
to be approved for the treatment of diabetic dyslipidemia is marketed by Zydus
Discovery, a division of Zydus Healthcare Ltd.
The Company reports that the doses of the vaccine administered to healthy
volunteers in the Phase I clinical trial, which began on 15th July 2020, has been well
tolerated. Previously, the vaccine was found to be safe, immunogenic and well
tolerated in the pre-clinical toxicity studies. The vaccine was able to elicit high level
of neutralizing antibodies in animal studies.
The company has commenced Phase II clinical trials from the 6 th of August, 2020.